Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma-Reference-Cited by-同舟云学术

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma

Published:2011-11-18 Issue:2 Volume:25 Page:282-288
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Katagiri Atsuko,Nakayama Kentaro,Rahman Mohammed Tanjimur,Rahman Munmun,Katagiri Hiroshi,Nakayama Naomi,Ishikawa Masako,Ishibashi Tomoka,Iida Kouji,Kobayashi Hiroshi,Otsuki Yoshiro,Nakayama Satoru,Miyazaki Kohji

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2011161.pdf

Reference33 articles.

1. Wingo PA, Tong T, Bolden S . Cancer statistics 1995. CA Cancer J Clin 1995;45:8–30.

2. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278–287.

3. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–2465.

4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.

5. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584–2589.

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer;International Journal of Gynecologic Cancer;2024-09-04

2. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

3. Epithelial tumors of the ovary: A review focusing on carcinoma and recent advances;Human Pathology Reports;2024-09

4. Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis;BMC Pulmonary Medicine;2024-07-02

5. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma;Journal of Translational Medicine;2024-06-10